Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA - Episode 4

The DREAMM-2 Trial

May 3, 2021
Sagar Lonial, MD, FACP

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.